Review



human cxcl1 gro alpha duoset elisa kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems human cxcl1 gro alpha duoset elisa kit
    Human Cxcl1 Gro Alpha Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 74 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cxcl1 gro alpha duoset elisa kit/product/R&D Systems
    Average 94 stars, based on 74 article reviews
    human cxcl1 gro alpha duoset elisa kit - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    94
    Multi Sciences (Lianke) Biotech Co Ltd human cxcl3 elisa kit
    Human Cxcl3 Elisa Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cxcl3 elisa kit/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 94 stars, based on 1 article reviews
    human cxcl3 elisa kit - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    R&D Systems human cxcl1 gro alpha duoset elisa kit
    Human Cxcl1 Gro Alpha Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cxcl1 gro alpha duoset elisa kit/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    human cxcl1 gro alpha duoset elisa kit - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    92
    Boster Bio human cxcl1 elisa kit
    Increased expression of <t>CXCL1</t> mRNA levels is associated with the clinical characteristics of patients with RCC. (A) The expression profiles of CXCL1 mRNA in normal tissues compared with ccRCC or pRCC tissues. The different levels of expression of CXCL1 mRNA within (B) different clinical grades and (C) subtypes of ccRCC tissues. Expression levels of CXCL1 mRNA in the (D) GSE53757 and the (E) GSE40435 datasets. The different levels of expression of CXCL1 mRNA within different (F) clinical grades and (G) stages of ccRCC tissues. Analysis of the expression level of CXCL1 within the clinical (H) T-status, (I) N-status and (J) M-status categories in ccRCC tissues. (K-M) A prognostic assessment was performed among the various groups. **P<0.01 vs. normal; # P<0.01 vs. normal, grade 1 and 2; ▲ P<0.01 vs. normal and ccA subtype. CXCL1, CXC motif chemokine ligand 1; RCC, renal cell carcinoma; ccRCC, clear cell RCC; pRCC, papillary RCC; T, tumor; N, lymph node; M, metastasis; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival.
    Human Cxcl1 Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cxcl1 elisa kit/product/Boster Bio
    Average 92 stars, based on 1 article reviews
    human cxcl1 elisa kit - by Bioz Stars, 2026-03
    92/100 stars
      Buy from Supplier

    90
    MultiSciences Biotech Co Ltd human cxcl2/gro- β elisa kit
    Increased expression of <t>CXCL1</t> mRNA levels is associated with the clinical characteristics of patients with RCC. (A) The expression profiles of CXCL1 mRNA in normal tissues compared with ccRCC or pRCC tissues. The different levels of expression of CXCL1 mRNA within (B) different clinical grades and (C) subtypes of ccRCC tissues. Expression levels of CXCL1 mRNA in the (D) GSE53757 and the (E) GSE40435 datasets. The different levels of expression of CXCL1 mRNA within different (F) clinical grades and (G) stages of ccRCC tissues. Analysis of the expression level of CXCL1 within the clinical (H) T-status, (I) N-status and (J) M-status categories in ccRCC tissues. (K-M) A prognostic assessment was performed among the various groups. **P<0.01 vs. normal; # P<0.01 vs. normal, grade 1 and 2; ▲ P<0.01 vs. normal and ccA subtype. CXCL1, CXC motif chemokine ligand 1; RCC, renal cell carcinoma; ccRCC, clear cell RCC; pRCC, papillary RCC; T, tumor; N, lymph node; M, metastasis; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival.
    Human Cxcl2/Gro β Elisa Kit, supplied by MultiSciences Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cxcl2/gro- β elisa kit/product/MultiSciences Biotech Co Ltd
    Average 90 stars, based on 1 article reviews
    human cxcl2/gro- β elisa kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    94
    Multi Sciences (Lianke) Biotech Co Ltd human cxcl1 gro α elisa kit ek196
    Increased expression of <t>CXCL1</t> mRNA levels is associated with the clinical characteristics of patients with RCC. (A) The expression profiles of CXCL1 mRNA in normal tissues compared with ccRCC or pRCC tissues. The different levels of expression of CXCL1 mRNA within (B) different clinical grades and (C) subtypes of ccRCC tissues. Expression levels of CXCL1 mRNA in the (D) GSE53757 and the (E) GSE40435 datasets. The different levels of expression of CXCL1 mRNA within different (F) clinical grades and (G) stages of ccRCC tissues. Analysis of the expression level of CXCL1 within the clinical (H) T-status, (I) N-status and (J) M-status categories in ccRCC tissues. (K-M) A prognostic assessment was performed among the various groups. **P<0.01 vs. normal; # P<0.01 vs. normal, grade 1 and 2; ▲ P<0.01 vs. normal and ccA subtype. CXCL1, CXC motif chemokine ligand 1; RCC, renal cell carcinoma; ccRCC, clear cell RCC; pRCC, papillary RCC; T, tumor; N, lymph node; M, metastasis; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival.
    Human Cxcl1 Gro α Elisa Kit Ek196, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cxcl1 gro α elisa kit ek196/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 94 stars, based on 1 article reviews
    human cxcl1 gro α elisa kit ek196 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    93
    Multi Sciences (Lianke) Biotech Co Ltd cxcl2
    Fibroblast‐specific FKBP5 deletion reduces pulmonary inflammation in septic ARDS. (A) Septic ARDS model using Col1a2 ‐iCre Fkbp5 flox/flox mice. (B) Immunofluorescence of FKBP5 in fibroblasts (200×; scale bar, 50 μm). (C) H&E‐stained lung sections and histopathology scoring (200×; scale bar, 50 μm). (D) FITC‐dextran assay of vascular permeability. (E) Neutrophil percentage in BALF measured by flow cytometry. (F, G) ELISA quantification of TNF‐α, IL‐1β, IL‐6, CXCL1, and <t>CXCL2</t> in BALF. (H) BALF levels of MPO and cfDNA. (I) TEM of glycocalyx (8000×; scale bar, 500 nm). (J) TEM of tight junctions (20,000×; scale bar, 200 nm). All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.
    Cxcl2, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cxcl2/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 93 stars, based on 1 article reviews
    cxcl2 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    Increased expression of CXCL1 mRNA levels is associated with the clinical characteristics of patients with RCC. (A) The expression profiles of CXCL1 mRNA in normal tissues compared with ccRCC or pRCC tissues. The different levels of expression of CXCL1 mRNA within (B) different clinical grades and (C) subtypes of ccRCC tissues. Expression levels of CXCL1 mRNA in the (D) GSE53757 and the (E) GSE40435 datasets. The different levels of expression of CXCL1 mRNA within different (F) clinical grades and (G) stages of ccRCC tissues. Analysis of the expression level of CXCL1 within the clinical (H) T-status, (I) N-status and (J) M-status categories in ccRCC tissues. (K-M) A prognostic assessment was performed among the various groups. **P<0.01 vs. normal; # P<0.01 vs. normal, grade 1 and 2; ▲ P<0.01 vs. normal and ccA subtype. CXCL1, CXC motif chemokine ligand 1; RCC, renal cell carcinoma; ccRCC, clear cell RCC; pRCC, papillary RCC; T, tumor; N, lymph node; M, metastasis; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Increased expression of CXCL1 mRNA levels is associated with the clinical characteristics of patients with RCC. (A) The expression profiles of CXCL1 mRNA in normal tissues compared with ccRCC or pRCC tissues. The different levels of expression of CXCL1 mRNA within (B) different clinical grades and (C) subtypes of ccRCC tissues. Expression levels of CXCL1 mRNA in the (D) GSE53757 and the (E) GSE40435 datasets. The different levels of expression of CXCL1 mRNA within different (F) clinical grades and (G) stages of ccRCC tissues. Analysis of the expression level of CXCL1 within the clinical (H) T-status, (I) N-status and (J) M-status categories in ccRCC tissues. (K-M) A prognostic assessment was performed among the various groups. **P<0.01 vs. normal; # P<0.01 vs. normal, grade 1 and 2; ▲ P<0.01 vs. normal and ccA subtype. CXCL1, CXC motif chemokine ligand 1; RCC, renal cell carcinoma; ccRCC, clear cell RCC; pRCC, papillary RCC; T, tumor; N, lymph node; M, metastasis; OS, overall survival; DSS, disease-specific survival; PFS, progression-free survival.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Expressing

    Expression levels of CXCL1 mRNA are correlated with the expression of genes implicated in tumorigenesis, recruitment of immune cells and presence of MSI in renal cell carcinoma. (A) Identification of 10 hub genes exhibiting co-expression with CXCL1. (B) Analysis of the protein-interaction network involving CXCL1. (C) Analysis of the correlation between CXCL1 and the aforementioned 10 hub genes. (D) Analysis of the correlation between CXCL1 expression and immune cell recruitment. The correlation between CXCL1 expression and the (E) number of mutations is presented, as well as (F) MSI scores. (G) The expression levels of CXCL1 in the MSI group compared with the MSS group. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. CXCL, CXC motif chemokine ligand; ACKR1, atypical chemokine receptor 1; CCR, C-C chemokine receptor type 2; MSI, microsatellite instability; MSS, microsatellite stable or no apparent MSI; TIMER, tumor immune estimation resource; TCGA, The Cancer Genome Atlas; T, tumor; N, normal.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Expression levels of CXCL1 mRNA are correlated with the expression of genes implicated in tumorigenesis, recruitment of immune cells and presence of MSI in renal cell carcinoma. (A) Identification of 10 hub genes exhibiting co-expression with CXCL1. (B) Analysis of the protein-interaction network involving CXCL1. (C) Analysis of the correlation between CXCL1 and the aforementioned 10 hub genes. (D) Analysis of the correlation between CXCL1 expression and immune cell recruitment. The correlation between CXCL1 expression and the (E) number of mutations is presented, as well as (F) MSI scores. (G) The expression levels of CXCL1 in the MSI group compared with the MSS group. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. CXCL, CXC motif chemokine ligand; ACKR1, atypical chemokine receptor 1; CCR, C-C chemokine receptor type 2; MSI, microsatellite instability; MSS, microsatellite stable or no apparent MSI; TIMER, tumor immune estimation resource; TCGA, The Cancer Genome Atlas; T, tumor; N, normal.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Expressing

    Protein levels of CXCL1 expression are markedly elevated in the tissues of patients with RCC. Representative images, illustrating strong-intensity staining of CXCL1 in (A) grade I, (B) grade II and (C) grade III RCC tissues. (D) Representative image, illustrating weak-intensity staining of CXCL1 in paracancerous tissues. CXCL1, CXC motif chemokine ligand 1; RCC, renal cell carcinoma.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Protein levels of CXCL1 expression are markedly elevated in the tissues of patients with RCC. Representative images, illustrating strong-intensity staining of CXCL1 in (A) grade I, (B) grade II and (C) grade III RCC tissues. (D) Representative image, illustrating weak-intensity staining of CXCL1 in paracancerous tissues. CXCL1, CXC motif chemokine ligand 1; RCC, renal cell carcinoma.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Expressing, Staining

    Exogenous CXCL1 treatment enhances the malignant phenotype of renal cell carcinoma cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay in (A) 786-O and (B) CAKI-2 cells. Representative images from Transwell assays with (C) 786-O and (D) CAKI-2 cells (magnification, ×100). Assessment of cell migration using a Transwell assay in (E) 786-O and (F) CAKI-2 cells. *P<0.05; **P<0.01 vs. 0 ng/ml. CXCL1, CXC motif chemokine ligand 1.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Exogenous CXCL1 treatment enhances the malignant phenotype of renal cell carcinoma cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay in (A) 786-O and (B) CAKI-2 cells. Representative images from Transwell assays with (C) 786-O and (D) CAKI-2 cells (magnification, ×100). Assessment of cell migration using a Transwell assay in (E) 786-O and (F) CAKI-2 cells. *P<0.05; **P<0.01 vs. 0 ng/ml. CXCL1, CXC motif chemokine ligand 1.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Cell Counting, Migration, Transwell Assay

    Overexpression of CXCL1 stimulates the malignant phenotype of renal cell carcinoma cells. Evaluation of CXCL3 expression in the supernatant from cell medium using ELISA assay in (A) 786-O and (B) CAKI-2 cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay with (C) 786-O and (D) CAKI-2 cells. Representative images from Transwell assay experiments with (E) 786-O and (F) CAKI-2 cells (magnification, ×100). Assessment of cell migration using Transwell assay with (G) 786-O and (H) CAKI-2 cells. **P<0.01 vs. control. CXCL1, CXC motif chemokine ligand 1.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Overexpression of CXCL1 stimulates the malignant phenotype of renal cell carcinoma cells. Evaluation of CXCL3 expression in the supernatant from cell medium using ELISA assay in (A) 786-O and (B) CAKI-2 cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay with (C) 786-O and (D) CAKI-2 cells. Representative images from Transwell assay experiments with (E) 786-O and (F) CAKI-2 cells (magnification, ×100). Assessment of cell migration using Transwell assay with (G) 786-O and (H) CAKI-2 cells. **P<0.01 vs. control. CXCL1, CXC motif chemokine ligand 1.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Over Expression, Expressing, Enzyme-linked Immunosorbent Assay, Cell Counting, Transwell Assay, Migration, Control

    Low expression of CXCL1 suppresses the malignant phenotype of renal cell carcinoma cells. Evaluation of CXCL3 expression in the supernatant from cell medium using ELISA assay with (A) 786-O and (B) CAKI-2 cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay with (C) 786-O and (D) CAKI-2 cells. Representative images from Transwell assay experiments (magnification, ×100) with (E) 786-O and (F) CAKI-2 cells. Assessment of cell migration using Transwell assay with (G) 786-O and (H) CAKI-2 cells. **P<0.1 01 vs. control. CXCL1, CXC motif chemokine ligand 1; siRNA, small interfering RNA.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Low expression of CXCL1 suppresses the malignant phenotype of renal cell carcinoma cells. Evaluation of CXCL3 expression in the supernatant from cell medium using ELISA assay with (A) 786-O and (B) CAKI-2 cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay with (C) 786-O and (D) CAKI-2 cells. Representative images from Transwell assay experiments (magnification, ×100) with (E) 786-O and (F) CAKI-2 cells. Assessment of cell migration using Transwell assay with (G) 786-O and (H) CAKI-2 cells. **P<0.1 01 vs. control. CXCL1, CXC motif chemokine ligand 1; siRNA, small interfering RNA.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Cell Counting, Transwell Assay, Migration, Control, Small Interfering RNA

    Overexpression of CXCL1 modulates the expression of PI3K/AKT pathway-associated proteins in renal cell carcinoma cells. Representative images from western blotting assays in (A) 786-O and (B) CAKI-2 cells. Semi-quantification of the protein expression levels of Bax, Bcl-2, PI3K and AKT in (C) 786-O and (D) CAKI-2 cells. **P<0.01 vs. control. CXCL1, CXC motif chemokine ligand 1; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; PI3K, phosphoinositide 3-kinase.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Overexpression of CXCL1 modulates the expression of PI3K/AKT pathway-associated proteins in renal cell carcinoma cells. Representative images from western blotting assays in (A) 786-O and (B) CAKI-2 cells. Semi-quantification of the protein expression levels of Bax, Bcl-2, PI3K and AKT in (C) 786-O and (D) CAKI-2 cells. **P<0.01 vs. control. CXCL1, CXC motif chemokine ligand 1; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; PI3K, phosphoinositide 3-kinase.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Over Expression, Expressing, Western Blot, Control

    Blocking AKT reverses the promoting effect of overexpression of CXCL1 on the malignant behaviors of renal cell carcinoma cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay in (A) 786-O and (B) CAKI-2 cells. (Representative images from Transwell assay experiments (magnification, ×100) with (C) 786-O and (D) CAKI-2 cells. Assessment of cell migration using Transwell assay with (E) 786-O and (F) CAKI-2 cells. (magnification, ×100). **P<0.01 compared with overexpression. CXCL1, CXC motif chemokine ligand 1.

    Journal: Oncology Letters

    Article Title: Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms

    doi: 10.3892/ol.2025.15372

    Figure Lengend Snippet: Blocking AKT reverses the promoting effect of overexpression of CXCL1 on the malignant behaviors of renal cell carcinoma cells. Assessment of cell proliferation using a Cell Counting Kit-8 assay in (A) 786-O and (B) CAKI-2 cells. (Representative images from Transwell assay experiments (magnification, ×100) with (C) 786-O and (D) CAKI-2 cells. Assessment of cell migration using Transwell assay with (E) 786-O and (F) CAKI-2 cells. (magnification, ×100). **P<0.01 compared with overexpression. CXCL1, CXC motif chemokine ligand 1.

    Article Snippet: Following 24 h culture, the supernatant was isolated via centrifugation at 4°C, 1,000 × g for 5 min, and a Human CXCL1 ELISA kit (cat. no. EK0722; Wuhan Boster Biological Technology, Ltd.) was employed to determine and quantify the level of CXCL1 in the supernatant, following precisely the manufacturer's instructions.

    Techniques: Blocking Assay, Over Expression, Cell Counting, Transwell Assay, Migration

    Fibroblast‐specific FKBP5 deletion reduces pulmonary inflammation in septic ARDS. (A) Septic ARDS model using Col1a2 ‐iCre Fkbp5 flox/flox mice. (B) Immunofluorescence of FKBP5 in fibroblasts (200×; scale bar, 50 μm). (C) H&E‐stained lung sections and histopathology scoring (200×; scale bar, 50 μm). (D) FITC‐dextran assay of vascular permeability. (E) Neutrophil percentage in BALF measured by flow cytometry. (F, G) ELISA quantification of TNF‐α, IL‐1β, IL‐6, CXCL1, and CXCL2 in BALF. (H) BALF levels of MPO and cfDNA. (I) TEM of glycocalyx (8000×; scale bar, 500 nm). (J) TEM of tight junctions (20,000×; scale bar, 200 nm). All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Journal: Cell Proliferation

    Article Title: FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome

    doi: 10.1111/cpr.70075

    Figure Lengend Snippet: Fibroblast‐specific FKBP5 deletion reduces pulmonary inflammation in septic ARDS. (A) Septic ARDS model using Col1a2 ‐iCre Fkbp5 flox/flox mice. (B) Immunofluorescence of FKBP5 in fibroblasts (200×; scale bar, 50 μm). (C) H&E‐stained lung sections and histopathology scoring (200×; scale bar, 50 μm). (D) FITC‐dextran assay of vascular permeability. (E) Neutrophil percentage in BALF measured by flow cytometry. (F, G) ELISA quantification of TNF‐α, IL‐1β, IL‐6, CXCL1, and CXCL2 in BALF. (H) BALF levels of MPO and cfDNA. (I) TEM of glycocalyx (8000×; scale bar, 500 nm). (J) TEM of tight junctions (20,000×; scale bar, 200 nm). All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Article Snippet: ELISA kits for TNF‐α (EK182, EK282), IL‐1β (EK101B, EK201B), IL‐6 (EK206), CXCL1 (EK196, EK296), and CXCL2 (EK1264, EK214) were sourced from Multi Sciences Biotech (Hangzhou, China).

    Techniques: Immunofluorescence, Staining, Histopathology, Permeability, Flow Cytometry, Enzyme-linked Immunosorbent Assay

    FKBP5 in mouse alveolar fibroblasts mediates LPS‐induced cytokine storms via necroptosis. (A) Schematic of enzyme‐digested fibroblast isolation and Scube2 + cell immunofluorescence (100×; scale bar, 100 μm). (B, C) Western blot of NF‐κB pathway proteins and cytokines (IL‐1β, TNF‐α, HMGB1) after LPS treatment (10 μg/mL, 6 h). (D) Volcano plot of differentially expressed genes (DEGs) ( p < 0.05, fold change ≥ 2). (E, F) Heatmaps of differentially expressed proteins. (G) Gene Ontology enrichment analysis of DEGs. (H, I) Western blot validation of necroptosis activation. (J) ELISA of CXCL1 and CXCL2 levels in fibroblast supernatant. All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Journal: Cell Proliferation

    Article Title: FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome

    doi: 10.1111/cpr.70075

    Figure Lengend Snippet: FKBP5 in mouse alveolar fibroblasts mediates LPS‐induced cytokine storms via necroptosis. (A) Schematic of enzyme‐digested fibroblast isolation and Scube2 + cell immunofluorescence (100×; scale bar, 100 μm). (B, C) Western blot of NF‐κB pathway proteins and cytokines (IL‐1β, TNF‐α, HMGB1) after LPS treatment (10 μg/mL, 6 h). (D) Volcano plot of differentially expressed genes (DEGs) ( p < 0.05, fold change ≥ 2). (E, F) Heatmaps of differentially expressed proteins. (G) Gene Ontology enrichment analysis of DEGs. (H, I) Western blot validation of necroptosis activation. (J) ELISA of CXCL1 and CXCL2 levels in fibroblast supernatant. All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Article Snippet: ELISA kits for TNF‐α (EK182, EK282), IL‐1β (EK101B, EK201B), IL‐6 (EK206), CXCL1 (EK196, EK296), and CXCL2 (EK1264, EK214) were sourced from Multi Sciences Biotech (Hangzhou, China).

    Techniques: Isolation, Immunofluorescence, Western Blot, Biomarker Discovery, Activation Assay, Enzyme-linked Immunosorbent Assay

    FKBP5 regulates necroptosis‐driven cytokine release in human alveolar fibroblasts. (A, B) Western blot analysis of NF‐κB signalling, IL‐1β, and TNF‐α after LPS stimulation (10 μg/mL, 6 h) with or without siRNA Fkbp5 . (C, D) Western blot of necroptosis markers in fibroblasts with siRNA Fkbp5 . (E, F) ELISA analysis of TNF‐α, IL‐1β, CXCL1, and CXCL2 in cell supernatant. All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Journal: Cell Proliferation

    Article Title: FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome

    doi: 10.1111/cpr.70075

    Figure Lengend Snippet: FKBP5 regulates necroptosis‐driven cytokine release in human alveolar fibroblasts. (A, B) Western blot analysis of NF‐κB signalling, IL‐1β, and TNF‐α after LPS stimulation (10 μg/mL, 6 h) with or without siRNA Fkbp5 . (C, D) Western blot of necroptosis markers in fibroblasts with siRNA Fkbp5 . (E, F) ELISA analysis of TNF‐α, IL‐1β, CXCL1, and CXCL2 in cell supernatant. All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Article Snippet: ELISA kits for TNF‐α (EK182, EK282), IL‐1β (EK101B, EK201B), IL‐6 (EK206), CXCL1 (EK196, EK296), and CXCL2 (EK1264, EK214) were sourced from Multi Sciences Biotech (Hangzhou, China).

    Techniques: Western Blot, Enzyme-linked Immunosorbent Assay

    FKBP5 mediates necroptosis‐induced inflammatory signalling in human alveolar fibroblasts. (A, B) Immunofluorescence of phosphorylated RIPK1, RIPK3, and MLKL after TSZ stimulation 9 h (200×; scale bar, 50 μm). (C, D) Western blot of NF‐κB signalling, HMGB1, IL‐1β, and TNF‐α. (E, F) siRNA Fkbp5 effect on TSZ‐induced necroptosis confirmed by Western blot. (G, H) Western blot showing suppression of NF‐κB signalling by siRNA Fkbp5 . (I) ELISA quantification of TNF‐α, IL‐1β, IL‐6, CXCL1, and CXCL2 in fibroblast supernatants. All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Journal: Cell Proliferation

    Article Title: FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome

    doi: 10.1111/cpr.70075

    Figure Lengend Snippet: FKBP5 mediates necroptosis‐induced inflammatory signalling in human alveolar fibroblasts. (A, B) Immunofluorescence of phosphorylated RIPK1, RIPK3, and MLKL after TSZ stimulation 9 h (200×; scale bar, 50 μm). (C, D) Western blot of NF‐κB signalling, HMGB1, IL‐1β, and TNF‐α. (E, F) siRNA Fkbp5 effect on TSZ‐induced necroptosis confirmed by Western blot. (G, H) Western blot showing suppression of NF‐κB signalling by siRNA Fkbp5 . (I) ELISA quantification of TNF‐α, IL‐1β, IL‐6, CXCL1, and CXCL2 in fibroblast supernatants. All data are presented as means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Article Snippet: ELISA kits for TNF‐α (EK182, EK282), IL‐1β (EK101B, EK201B), IL‐6 (EK206), CXCL1 (EK196, EK296), and CXCL2 (EK1264, EK214) were sourced from Multi Sciences Biotech (Hangzhou, China).

    Techniques: Immunofluorescence, Western Blot, Enzyme-linked Immunosorbent Assay